Nove znanstvene objave

Spisek izbranih novejših znanstvenih objav na temo psihedelikov in širše

(A list of selected scientific publications on the topic of psychedelics and related issues)


Za obširnejšo bibliografijo si lahko pomagate z iskalniki MAPS Psychedelic Bibliography, Erowid references, PubMed in Google Scholar. Če potrebujete katerega od spodaj naštetih člankov, pa do ustrezne revije nimate dostopa, nam pišite po elektronski pošti.


Graf števila znanstvenih objav na leto za obdobje 1955 do 2015, ki so bili indeksiranih v bibliografski bazi Web of Science pod ključnimi besedami "psychedelic", "psychotomimetic" ali "hallucinogen".

Graf števila znanstvenih objav na posamezno leto za obdobje 1955 do 2015, ki so bile indeksirane v bibliografski bazi Web of Science pod ključnimi besedami “psychedelic”, “psychotomimetic” ali “hallucinogen”.





Use of synthetic stimulants and hallucinogens in a cohort of electronic dance music festival attendees
Amanda L. A. Mohr, Melissa Friscia, Jillian K.Yeakel, Barry K. Logan
Forensic Science International, 2018, 282, 168-178. DOI: 10.1016/j.forsciint.2017.11.017





Psychedelics and reconsolidation of traumatic and appetitive maladaptive memories: focus on cannabinoids and ketamine
Liana Fattore, Alessandro Piva, Mary Tresa Zanda, Guido Fumagalli, Cristiano Chiamulera
Psychopharmacology, 2017, v tisku. DOI: 10.1007/s00213-017-4793-4


Studies with psychedelic drugs in human volunteers
Edward M. Sellers, Myroslava K. Romach, Deborah B. Leiderman
Neuropharmacology, 2017, v tisku. DOI: 10.1016/j.neuropharm.2017.11.029


Ayahuasca and Kambo intoxication after alternative natural therapy for depression, confirmed by mass spectrometry
Damila Rodrigues de Morais, Rafael Lanaro, Ingrid Lopes Barbosa, Jandyson Machado Santos, Kelly Francisco Cunha, Vinicius Veri Hernandes, Elias Paulo Tessaro, Cezar Silvino Gomes, Marcos Nogueira Eberlin, Jose Luiz Costa
Forensic Toxicology, 2017, v tisku. DOI: 10.1007/s11419-017-0394-5


Regulation of human research with LSD in the United States (1949-1987)
Katherine R. Bonson
Psychopharmacology, 2017, v tisku. DOI: 10.1007/s00213-017-4777-4


Well-being, problematic alcohol consumption and acute subjective drug effects in past-year ayahuasca users: a large, international, self-selecting online survey
Will Lawn, Jaime E. Hallak, Jose A. Crippa, Rafael Dos Santos, Lilla Porffy, Monica J. Barratt, Jason A. Ferris, Adam R. Winstock, Celia J. A. Morgan
Scientific Reports 7, 2017, 15201. DOI: 10.1038/s41598-017-14700-6


LSD Increases Primary Process Thinking via Serotonin 2A Receptor Activation
Rainer Kraehenmann, Dan Pokorny, Helena Aicher, Katrin H. Preller, Thomas Pokorny, Oliver G. Bosch, Erich Seifritz, Franz X. Vollenweider
Front. Pharmacol., 2017, v tisku. DOI: 10.3389/fphar.2017.00814


Why MDMA therapy for alcohol use disorder? And why now?
Ben Sessa
Neuropharmacology, 2017, v tisku. DOI: 10.1016/j.neuropharm.2017.11.004


Double-blind comparison of the two hallucinogens psilocybin and dextromethorphan: similarities and differences in subjective experiences
Theresa M. Carbonaro, Matthew W. Johnson, Ethan Hurwitz, Roland R. Griffiths
Psychopharmacology, 2017, v tisku. DOI: 10.1007/s00213-017-4769-4


LSD modulates effective connectivity and neural adaptation mechanisms in an auditory oddball paradigm
Christopher Timmermann, Meg J. Spriggs, Mendel Kaelen, Robert Leech, David J.Nutt, Rosalyn J.Moran, Robin L. Carhart-Harris, Suresh D. Muthukumaraswamy
Neuropharmacology, 2017, v tisku. DOI: 10.1016/j.neuropharm.2017.10.039


N,N-dimethyltryptamine and the pineal gland: Separating fact from myth
David E Nichols
Journal of Psychopharmacology, 2017, v tisku. DOI: 10.1177/0269881117736919


Additive Effects of 3,4-Methylenedioxymethamphetamine (MDMA) and Compassionate Imagery on Self-Compassion in Recreational Users of Ecstasy
S. K. Kamboj, Y. S. E. Walldén, C. J. Falconer, et al.
Mindfulness, 2017, v tisku. DOI: 10.1007/s12671-017-0849-0


Psilocybin with psychological support improves emotional face recognition in treatment-resistant depression
J. B. Stroud, T. P. Freeman, R. Leech, C. Hindocha, W. Lawn, D. J. Nutt, H. V Curran, R. L. Carhart-Harris
Psychopharmacology, 2017, v tisku. DOI: 10.1007/s00213-017-4754-y


The relationships of classic psychedelic use with criminal behavior in the United States adult population
Peter S Hendricks, Michael Scott Crawford, Karen L Cropsey, Heith Copes, N Wiles Sweat, Zach Walsh, Gregory Pavela
Journal of Psychopharmacology, 2017, v tisku. DOI: 10.1177/0269881117735685


Perceptions of the medicinal value of hallucinogenic drugs among college students
Wildberger Jared I., John Cassandra N. Hallock Robert M.
Journal of Psychedelic Studies, 2017, v tisku. DOI: 10.1556/2054.01.2017.008


Subjective effectiveness of ibogaine treatment for problematic opioid consumption: Short- and long-term outcomes and current psychological functioning
Davis Alan K., Barsuglia Joseph P., Windham-Herman Austin-Marley, Lynch Marta, Polanco Martin
Journal of Psychedelic Studies, 2017, v tisku. DOI: 10.1556/2054.01.2017.009


Short term changes in the proteome of human cerebral organoids induced by 5-MeO-DMT
Vanja Dakić, Juliana Minardi Nascimento, Rafaela Costa Sartore, Renata de Moraes Maciel, Draulio B. de Araujo, Sidarta Ribeiro, Daniel Martins-de-Souza, Stevens K. Rehen
Scientific Reports, 2017, 7: 12863. DOI: 10.1038/s41598-017-12779-5


Psilocybin-occasioned mystical-type experience in combination with meditation and other spiritual practices produces enduring positive changes in psychological functioning and in trait measures of prosocial attitudes and behaviors
Roland R Griffiths, , Matthew W Johnson, William A Richards, Brian D Richards, Robert Jesse, Katherine A MacLean, Frederick S Barrett, Mary P Cosimano, Maggie A Klinedinst
Journal of Psychopharmacology, 2017, v tisku. DOI: 10.1177/0269881117731279


Investigation into pharmacokinetic properties of active alkaloid ibogaine and its metabolite noribogaine
Asta Kubiliene, Audrius Sveikata, Andrejus Zevzikovas, Ilona Sadauskiene, Leonid Ivanov
Acta Poloniae Pharmaceutica – Drug Research, 2017, 74, 1591-1597.


TCB-2 [(7R)-3-bromo-2, 5-dimethoxy-bicyclo[4.2.0]octa-1,3,5-trien-7-yl]methanamine]: A hallucinogenic drug, a selective 5-HT2A receptor pharmacological tool, or none of the above?
Giuseppe Di Giovanni, Philippe De Deurwaerdère
Neuropharmacology, 2017, v tisku. DOI: 10.1016/j.neuropharm.2017.10.004


Acute LSD effects on response inhibition neural networks
A. Schmidt, F. Müller, C. Lenz, P. C. Dolder, Y. Schmid, D. Zanchi, U. E. Lang, M. E. Liechti, S. Borgwardt
Psychological Medicine, 2017, v tisku. DOI: 10.1017/S0033291717002914


The Mechanisms of Psychedelic Visionary Experiences: Hypotheses from Evolutionary Psychology
Michael J. Winkelman
Front. Neurosci., 2017, v tisku. DOI: 10.3389/fnins.2017.00539


Serotonin 2A Receptor Signaling Underlies LSD-induced Alteration of the Neural Response to Dynamic Changes in Music
Frederick S. Barrett, Katrin H. Preller, Marcus Herdener, Petr Janata, Franz X. Vollenweider
Cerebral Cortex, 2017, v tisku. DOI: 10.1093/cercor/bhx257


Acute LSD effects on response inhibition neural networks
A. Schmidt, F. Müller, C. Lenz, P. C. Dolder
Psychological Medicine, 2017, v tisku. DOI: 10.1017/S0033291717002914


Does psychedelic drug use reduce risk of suicidality? Evidence from a longitudinal community-based cohort of marginalised women in a Canadian setting
Elena Argento, Steffanie A Strathdee, Kenneth Tupper, Melissa Braschel, Evan Wood, Kate Shannon
BMJ Open, 2017, 7: e016025. DOI: 10.1136/bmjopen-2017-016025


Psychedelic Drugs in Biomedicine
Evan J. Kyzar,  Charles D. Nichols, Raul R. Gainetdinov, David E. Nichols, Allan V. Kalueff
Trends in Pharmacological Sciences, 2017, v tisku. DOI: 10.1016/


Serotonergic hallucinogens in the treatment of anxiety and depression in patients suffering from a life-threatening disease: A systematic review
Simon Reiche, Leo Hermle, Stefan Gutwinski, Henrik Jungaberle, Peter Gasser, Tomislav Majić
Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2017, v tisku. DOI: 10.1016/j.pnpbp.2017.09.012


Long-lasting subjective effects of LSD in normal subjects
Yasmin Schmid, Matthias E. Liechti
Psychopharmacology, 2017, v tisku. DOI: 10.1007/s00213-017-4733-3


Longitudinal Examination of Learning and Memory in Rats Following Adolescent Exposure to 3,4-Methylenedioxymethamphetamine or 5-Methoxy-N,N-Diisopropyltryptamine
David M. Compton, Kerri L. Dietrich, Peniel Esquivel, Corina Garcia
Journal of Behavioral and Brain Science, 2017, 7, 371-398. DOI: 10.4236/jbbs.2017.79028


Serotonin and brain function: a tale of two receptors
R. L. Carhart-Harris, D. J. Nutt
J. Psychopharmacol., 2017, 31, 1091-1120. DOI: 10.1177/0269881117725915


Ayahuasca: what mental health professionals need to know
Rafael Guimarães dos Santos, José Carlos Bouso, Jaime Eduardo Cecilio Hallak
Archives of Clinical Psychiatry, 2017, 44, v tisku. DOI: 10.1590/0101-60830000000130
pregledni članek


A phenomenological analysis of the subjective experience elicited by ibogaine in the context of a drug dependence treatment
Eduardo Ekman Schenberg, Maria Angélica de Castro Comis, João Felipe Morel Alexandre, Luís Fernando Tófoli, Bruno Daniel Rasmussen Chaves, Dartiu Xavier da Silveira
Journal of Psychedelic Studies, 2017, v tisku. DOI: 10.1556/2054.01.2017.007


MDA, MDMA and other mescaline-like substances in the US military’s search for a truth drug (1940s to 1960s)
T. Passie, U. Benzenhöfer
Drug Test Anal., 2017, v tisku. DOI: 10.1002/dta.2292


Ayahuasca, Technical Report 2017
José Carlos Bouso, Rafael Guimarães dos Santos, Charles S. Grob, Dartiu Xavier da Silveira, Dennis Jon McKenna, Draulio Barros de Araujo, Jordi Riba, Paulo Cesar Ribeiro Barbosa, Constanza Sánchez Aviléz, Beatriz Caiuby Labate


Enzymatic Synthesis of Psilocybin
J. Fricke, F. Blei, D. Hoffmeister
Angew. Chem. Int. Ed., 2017, 56, 12352. DOI: 10.1002/anie.201705489

Medijski odzivi: Magic enzymes in ‘magic’ mushrooms analyzed


Horizontal gene cluster transfer increased hallucinogenic mushroom diversity
Hannah T. Reynolds, Vinod Vijayakumar, Emile Gluck-Thaler, Hailee B. Korotkin, Patrick B. Matheny, Jason C. Slot
bioRxiv, 2017, v tisku. DOI: 10.1101/176347

Medijski odzivi: Magic mushroom chemical may be a hallucinogenic insect repellent


Psychedelic Drugs as Therapeutics: No Illusions About the Challenges
E. M. Sellers, D. B. Leiderman
Clin. Pharmacol. Ther., 2017, v tisku. DOI: 10.1002/cpt.776


The 21st century psychedelic renaissance: heroic steps forward on the back of an elephant
Ben Sessa
Psychopharmacology, 2017, v tisku. DOI: 10.1007/s00213-017-4713-7


Pharmacological studies of Syrian rue (Peganum harmala L., Zygophyllaceae)
Nazim A Mamedov, Ardalan Pasdaran, Nilufar Z. Mamadalieva
International Journal of Secondary Metabolite, 2017, 5, v tisku. DOI: 10.21448/ijsm.335539


Naturalizing psychedelic spirituality
Letheby Chris
Zygon, 2017, 52, 623-642. DOI: 10.1111/zygo.12353


Entheogenesis: Toward an Expanded Worldview for Our Time
Ralph Metzner
Journal of Humanistic Psychology, 2017, 57, 443-449. DOI: 10.1177/0022167817723405


Psychedelics and connectedness
Carhart-Harris, R.L., Erritzoe, D., Haijen, E. et al.
Psychopharmacology, 2017, v tisku. DOI: 10.1007/s00213-017-4701-y


Screening of Hallucinogenic Compounds and Genomic Characterisation of 40 Anatolian Salvia Species
Hatipoglu, S. D., Yalcinkaya, B., Akgoz, M., Ozturk, T., Goren, A. C., and Topcu, G.
Phytochem. Anal., 2017, v tisku. DOI: 10.1002/pca.2703


Psychedelic drug use in healthy individuals: A review of benefits, costs, and implications for drug policy
James W.B. Elsey
Drug Science, Policy and Law, 2017, v tisku. DOI: 10.1177/2050324517723232


Behavioral Changes Over Time Following Ayahuasca Exposure in Zebrafish
Robson Savoldi, Daniel Polari, Jaquelinne Pinheiro-da-Silva, Priscila F. Silva, Bruno Lobao-Soares, Mauricio Yonamine, Fulvio A. M. Freire, Ana C. Luchiari
Front. Behav. Neurosci., 2017, v tisku. DOI: 10.3389/fnbeh.2017.00139


The hyperassociative mind: The psychedelic experience and Merleau-Ponty’s “wild being”
Csaba Szummer, Lajos Horváth, Attila SzabÓ, Ede Frecska, KristÓf OrzÓi
Journal of Psychedelic Studies, 2017, v tisku. DOI: 10.1556/2054.01.2017.006


Qualitative and Quantitative Features of Music Reported to Support Peak Mystical Experiences during Psychedelic Therapy Sessions
Frederick S. Barrett, Hollis Robbins, David Smooke, Jenine L. Brown, Roland R. Griffiths
Front. Psychol., 2017, v tisku. DOI: 10.3389/fpsyg.2017.01238


Monoamine receptor interaction profiles of 4-thio-substituted phenethylamines (2C-T drugs)
Dino Luethi, Daniel Trachsel, Marius C. Hoener, Matthias E. Liechti
Neuropharmacology, 2017, v tisku. DOI: 10.1016/j.neuropharm.2017.07.012


Two dose investigation of the 5-HT-agonist psilocybin on relative and global cerebral blood flow
Candace R. Lewis, Katrin H. Preller, Rainer Kraehenmann, Lars Michels, Philipp Staempfli, Franz X. Vollenweider
NeuroImage, 2017, 159, 70–78. DOI: 10.1016/j.neuroimage.2017.07.020


LSD experiments by the United States Army
Colin A Ross
History of Psychiatry, 2017, v tisku. DOI: 10.1177/0957154X17717678


Developing Guidelines and Competencies for the Training of Psychedelic Therapists
Janis Phelps
Journal of Humanistic Psychology, 2017, v tisku. DOI: 10.1177/0022167817711304


MDMA-induced dissociative state not mediated by the 5-HT2A receptor
Drew J. Puxty, Johannes G. Ramaekers, Rafael de la Torre, Magí Farré, Neus Pizarro, Mitona Pujadas, Kim P. Kuypers
Front. Pharmacol., 2017, v tisku. DOI: 10.3389/fphar.2017.00455


A Single Dose of LSD Does Not Alter Gene Expression of the Serotonin 2A Receptor Gene (HTR2A) or Early Growth Response Genes (EGR1-3) in Healthy Subjects
Patrick C. Dolder, Edna Grünblatt, Felix Müller, Stefan J. Borgwardt, Matthias E. Liechti
Front. Pharmacol., 2017, v tisku. DOI: 10.3389/fphar.2017.00423


Therapeutic effect of increased openness: Investigating mechanism of action in MDMA-assisted psychotherapy
Mark T Wagner, Michael C. Mithoefer, Ann T. Mithoefer, Rebecca K. MacAulay, Lisa Jerome, Berra Yazar-Klosinski, Rick Doblin
Journal of Psychopharmacology, 2017, v tisku. DOI: 10.1177/0269881117711712


Patients’ Accounts of Increased “Connectedness” and “Acceptance” After Psilocybin for Treatment-Resistant Depression
Rosalind Watts, Camilla Day, Jacob Krzanowski, David Nutt, Robin Carhart-Harris
Journal of Humanistic Psychology, 2017, v tisku. DOI: 10.1177/0022167817709585


Lifetime experience with (classic) psychedelics predicts pro-environmental behavior through an increase in nature relatedness
Matthias Forstmann, Christina Sagioglou
Journal of Psychopharmacology, 2017, v tisku. DOI: 10.1177/0269881117714049


Neuroticism is associated with challenging experiences with psilocybin mushrooms
Frederick S. Barrett, Matthew W. Johnson, Roland R. Griffiths
Personality and Individual Differences, 2017, 117, 155–160. DOI: 10.1016/j.paid.2017.06.004


Potential Therapeutic Effects of Psilocybin
M. W. Johnson, R. R. Griffiths
Neurotherapeutics, 2017, v tisku. DOI: 10.1007/s13311-017-0542-y


Treatment of opioid use disorder with ibogaine: detoxification and drug use outcomes
Thomas Kingsley Brown, Kenneth Alper
The American Journal of Drug and Alcohol Abuse, 2017, v tisku. DOI: 10.1080/00952990.2017.1320802


Chronic intermittent exposure to ayahuasca during aging does not affect memory in mice
N. F. Correa-Netto, L. S. Coelho, G. S. Galfano, F. Nishide, F. Tamura, M. K. Shimizu et al.
Braz. J. Med. Biol. Res., 2017, 50, e6037. DOI: 10.1590/1414-431×20176037


An ontogenic study of the behavioral effects of chronic intermittent exposure to ayahuasca in mice
N. F. Correa-Netto, M. Y. Masukawa, F. Nishide, G. S. Galfano, F. Tamura, M. K. Shimizo et al.
Braz. J. Med. Biol. Res., 2017, 50, e6036. DOI: 10.1590/1414-431×20176036


Potential Use of Ayahuasca in Grief Therapy
Débora González, María Carvalho, Jordi Cantillo, Marc Aixalá, Magí Farré
OMEGA – Journal of Death and Dying, 2017, v tisku. DOI: 10.1177/0030222817710879


Psilocybin: Good Trip or Bad Trip
Sellers, E.
Clin. Pharmacol. Ther., 2017, v tisku. DOI: 10.1002/cpt.697


Harmine is an inflammatory inhibitor through the suppression of NF-κB signaling
Xin Liu, Mingxia Li, Si Tan, Changhong Wang, Shengjie Fan, Cheng Huang
Biochemical and Biophysical Research Communications, 2017, 489, 332–338. DOI: 10.1016/j.bbrc.2017.05.126


Ayahuasca Modifies Amphetamine Self Ingestion and Modifies Anxiety and Locomotor Activity in Adolescent Rats
A. F. Godinho, M. C. Silva, J. D. Kawashima, D. F. Horta, F. Anselmo, D. De Fraia
Electronic Journal of Biology, 2017, 13, 159-165.


Assessing the psychedelic “after-glow” in ayahuasca users: post-acute neurometabolic and functional connectivity changes are associated with enhanced mindfulness capacities
F. Sampedro, M. de la Fuente Revenga, M. Valle, N. Roberto, E. Domínguez-Clavé, M. Elices, L. Eduardo Luna, J. A. S. Crippa, J. E. C. Hallak, D. B. de Araujo, P. Friedlander, S. A. Barker, E. Álvarez, J. Soler, J. C. Pascual, A. Feilding, J. Riba
Int. J. Neuropsychopharmacol., 2017, pyx036. DOI: 10.1093/ijnp/pyx036


Genie in a blotter: A comparative study of LSD and LSD analogues’ effects and user profile
L. D. Coney, L. J. Maier, J. A. Ferris, A. R. Winstock, M. J. Barratt
Hum Psychopharmacol Clin Exp., 2017, e2599. DOI: 10.1002/hup.2599


Psychedelics As A New Anti-Inflammatory Therapeutic For Atherosclerosis
Charles D. Nichols, Melaine Sebastia, Thomas Flanagan
The FASEB Journal, 2017, 31, Supplement 825.3


Elucidating Functional Selectivity at the 5-HT2A Receptor
Gerald Billac, Charles Nichols
The FASEB Journal, 2017, 31, Supplement 663.2


Why Psychiatry Needs 3,4-Methylenedioxymethamphetamine: A Child Psychiatrist’s Perspective
B. Sessa
Neurotherapeutics, 2017, v tisku. DOI: 10.1007/s13311-017-0531-1


Patient Experiences of Psilocybin-Assisted Psychotherapy: An Interpretative Phenomenological Analysis
Alexander B. Belser, Gabrielle Agin-Liebes, T. Cody Swift, Sara Terrana, Neşe Devenot, Harris L. Friedman, Jeffrey Guss, Anthony Bossis, Stephen Ross
Journal of Humanistic Psychology, 2017, v tisku. DOI: 10.1177/0022167817706884


The Therapeutic Potential of Psychedelic Drugs: Past, Present and Future
Robin L. Carhart-Harris, Guy M. Goodwin
Neuropsychopharmacology, 2017, v tisku. DOI: 10.1038/npp.2017.84


Psychedelics, Personality and Political Perspectives
Matthew M. Nour, Lisa Evans, Robin L. Carhart-Harris
Journal of Psychoactive Drugs, 2017, v tisku. DOI: 10.1080/02791072.2017.1312643


Detoxification from methadone using low, repeated, and increasing doses of ibogaine: A case report
Clare Wilkins, Rafael G. dos Santos, Jordi Solá, Marc Aixalá, Pep Cura, Estefanía Moreno, Miguel Ángel Alcázar-Córcoles, Jaime E. C. Hallak, Jose Carlos Bouso
Journal of Psychedelic Studies, 2017, v tisku. DOI: 10.1556/2054.01.2017.005


Anxiety, panic, and hopelessness during and after ritual ayahuasca intake in a woman with generalized anxiety disorder: A case report
Rafael G. dos Santos, Flávia L. Osório, José Alexandre S. Crippa, Ribeirão Preto, Jaime E. C. Hallak
Journal of Psychedelic Studies, 2017, 1, 35-39. DOI: 10.1556/2054.01.2017.004


Ayahuasca’s entwined efficacy: An ethnographic study of ritual healing from ‘addiction’
Piera Talin, Emilia Sanabri
International Journal of Drug Policy, 2017, 44, 23–30. DOI: 10.1016/j.drugpo.2017.02.017


Increased spontaneous MEG signal diversity for psychoactive doses of ketamine, LSD and psilocybin
Michael M. Schartner, Robin L. Carhart-Harris, Adam B. Barrett, Anil K. Seth, Suresh D. Muthukumaraswamy
Scientific Reports, 2017, 7, 46421. DOI: 10.1038/srep46421


Analysis of the differences between hallucinations caused by natural hallucinogens and schizophrenia
Kristofer L. Korth
Eukaryon, 2017.


Chemistry and Structure–Activity Relationships of Psychedelics
David E. Nichols
Current Topics in Behavioral Neurosciences, 2017, v tisku. DOI: 10.1007/7854_2017_475


Classic Hallucinogens and Mystical Experiences: Phenomenology and Neural Correlates
Frederick S. Barrett, Roland R. Griffiths
Current Topics in Behavioral Neurosciences, 2017, v tisku. DOI: 10.1007/7854_2017_474


Dreamlike effects of LSD on waking imagery in humans depend on serotonin 2A receptor activation
Rainer Kraehenmann, Dan Pokorny, Leonie Vollenweider, Katrin H. Preller, Thomas Pokorny, Erich Seifritz, Franz X. Vollenweider
Psychopharmacology, 2017, v tisku. DOI: 10.1007/s00213-017-4610-0


Detailed characterization of the in vitro pharmacological and pharmacokinetic properties of N-(2-hydroxybenzyl)-2,5-dimethoxy-4-cyanophenylethylamine (25CN-NBOH), a highly selective and brain-penetrant 5-HT2A receptor agonist
A. A. Jensen, J. D. McCorvy, S. L. Petersen, C. Bundgaard, G. Liebscher, T. P. Kenakin, H. Bräuner-Osborne, J. Kehler, J. L. Kristensen
Journal of Pharmacology and Experimental Therapeutics, 2017, v tisku. DOI: 10.1124/jpet.117.239905


A single administration of the hallucinogen, 4-acetoxy-dimethyltryptamine, prevents the shift to a drug-dependent state and the expression of withdrawal aversions in rodents
Authors: Hector Vargas-Perez, Taryn E. Grieder, Ryan Ting-A-Kee, Geith Maal-Bared, Michal Chwalek, Derek van der Kooy
European Journal of Neuroscience, 2017, v tisku. DOI: 10.1111/ejn.13572


Hallucinogenic Drugs: A New Study Answers Old Questions about LSD
Adam L. Halberstadt
Current Biology, 2017, 27, R139–R161. DOI: 10.1016/j.cub.2016.12.058


Acute effects of LSD on amygdala activity during processing of fearful stimuli in healthy subjects
F. Mueller, C. Lenz, P. C. Dolder, S. Harder, Y. Schmid, U. E. Lang, M. E. Liechti, S. Borgwardt
Translational Psychiatry, 2017, 7, e1084. DOI: 10.1038/tp.2017.54


Pharmacokinetics of Escalating Doses of Oral Psilocybin in Healthy Adults
Randall T. Brown, Christopher R. Nicholas, Nicholas V. Cozzi, Michele C. Gassman, Karen M. Cooper, Daniel Muller, Chantelle D. Thomas, Scott J. Hetzel, Kelsey M. Henriquez, Alexandra S. Ribaudo, Paul R. Hutson
Clinical Pharmacokinetics, 2017, v tisku. DOI: 10.1007/s40262-017-0540-6


In vitro monoamine oxidase inhibition potential of alpha-methyltryptamine analog new psychoactive substances for assessing possible toxic risks
Lea Wagmann, Simon D. Brandt, Pierce V. Kavanagh, Hans H. Maurer, Markus R. Meye
Toxicology Letters, 2017, v tisku. DOI: 10.1016/j.toxlet.2017.03.007


Reproductive effects of the psychoactive beverage ayahuasca in male Wistar rats after chronic exposure
Alana de Fátima Andrade Santosa, Ana Luiza Sarkis Vieirab, Aline Pic-Taylorc, Eloisa Dutra Caldas
Revista Brasileira de Farmacognosia, 2017, v tisku. DOI: 10.1016/j.bjp.2017.01.006


Examination of the Phenomenology of the Ibogaine Treatment Experience: Role of Altered States of Consciousness and Psychedelic Experiences
Annamarie Heink, Steve Katsikas, Tiffany Lange-Altman
Journal of Psychoactive Drugs, 2017, v tisku. DOI: 10.1080/02791072.2017.1290855


Effects of Hallucinogens on Neuronal Activity
L. Lladó-Pelfort, P. Celada, M. S. Riga, E. Troyano-Rodríguez, N. Santana, F. Artigas
Current Topics in Behavioral Neurosciences, 2017, v tisku. DOI: 10.1007/7854_2017_473


Ayahuasca dimethyltryptamine, and psychosis: a systematic review of human studies
Rafael G. dos Santos, José Carlos Bouso, Jaime E. C. Hallak
Therapeutic Advances in Psychopharmacology, 2017, v tisku. DOI: 10.1177/2045125316689030


Psychedelics and the science of self-experience
Matthew M. Nour, Robin L. Carhart-Harris
The British Journal of Psychiatry, 2017, 210, 177-179. DOI: 10.1192/bjp.bp.116.194738


Effect of Hallucinogens on Unconditioned Behavior
Adam L. Halberstadt, Mark A. Geyer
Current Topics in Behavioral Neurosciences, 2017, v tisku. DOI: 10.1007/7854_2016_466


Short term changes in the proteome of human cerebral organoids induced by 5-methoxy-N, N-dimethyltryptamine
V. Dakic, J. Minardi Nascimento, R. Costa Sartore, R. de Moraes Maciel, D. B. de Araujo, S. Ribeiro, D. Martins-de-Souza, S. Rehen
bioRxiv – The preprint server for biology, 2017. DOI: 10.1101/108159


The association of psychedelic use and opioid use disorders among illicit users in the United States
V. D. Pisano, N. P. Putnam, H. M. Kramer, K. J. Franciotti, J. H. Halpern, S. C. Holden
Journal of Psychopharmacology, 2017, v tisku. DOI: 10.1177/0269881117691453


Science, spirituality, and ayahuasca: The problem of consciousness and spiritual ontologies in the academy
Ismael Apud
Zygon®, 2017, 52, 100–123. DOI: 10.1111/zygo.12315


Pharmacokinetics and Pharmacodynamics of Lysergic Acid Diethylamide in Healthy Subjects
P. C. Dolder, Y. Schmid, A. E. Steuer, T. Kraemer, K. M. Rentsch, F. Hammann, M. E. Liechti
Clinical Pharmacokinetics, 2017, v tisku. DOI: 10.1007/s40262-017-0513-9


A unique natural selective kappa-opioid receptor agonist, salvinorin A, and its roles in human therapeutics
A. Cruz, S. Domingos, E. Gallardo, A. Martinho
Phytochemistry, 2017, 137, 9–14. DOI: 10.1016/j.phytochem.2017.02.001


The Fabric of Meaning and Subjective Effects in LSD-Induced States Depend on Serotonin 2A Receptor Activation
K. H. Preller, M. Herdener, T. Pokorny, A. Planzer, R. Kraehenmann, P. Stämpfli, M. E. Liechti, E. Seifritz, F. X. Vollenweider
Current Biology, 2017, 27, 451–457. DOI: 10.1016/j.cub.2016.12.030


Rapid antidepressant effects of the psychedelic ayahuasca in treatment-resistant depression: a randomised placebo-controlled trial
F. Palhano-Fontes et al.
bioRxiv – The preprint server for biology, 2017. DOI: 10.1101/103531


Crystal Structure of an LSD-Bound Human Serotonin Receptor
Daniel Wacker, Sheng Wang, John D. McCorvy, Robin M. Betz, A.J. Venkatakrishnan, Anat Levit, Katherine Lansu, Zachary L. Schools, Tao Che, David E. Nichols, Brian K. Shoichet, Ron O. Dror, Bryan L. Roth
Cell, 2017, 168, 377–389, e12. DOI: 10.1016/j.cell.2016.12.033


The fibrinolytic system: A new target for treatment of depression with psychedelics
R. D. Idell, G. Florova, A. A. Komissarov, S. Shetty, R. B. S. Girard, S. Idell
Medical Hypotheses, 2017, 100, 46–53. DOI: 10.1016/j.mehy.2017.01.013


Determination of Tryptamines and β-Carbolines in Ayahuasca Beverage Consumed During Brazilian Religious Ceremonies
M. C. Santos, S. Navickiene, A. Gaujac
Journal of AOAC International, 2017, v tisku. DOI: 10.5740/jaoacint.16-0337


Pharmacology and Toxicology of N-Benzylphenethylamine (“NBOMe”) Hallucinogens
Adam L. Halberstadt
Current Topics in Behavioral Neurosciences, 2017, v tisku. DOI: 10.1007/7854_2016_64


Self-Transcendence Correlates with Brain Function Impairment
Bernardo Kastrup
Journal of Cognition and Neuroethics, 2017, 4, 33–42.


Constructing drug effects: A history of set and setting
Ido Hartogsohn
Drug Science, Policy and Law, 2017, 3, v tisku. DOI: 10.1177/2050324516683325


An online survey of tobacco smoking cessation associated with naturalistic psychedelic use
Matthew W Johnson, Albert Garcia-Romeu, Patrick S Johnson, Roland R Griffiths
Journal of Psychopharmacology, 2017, v tisku. DOI: 10.1177/0269881116684335


Weak phantasy and visionary phantasy: the phenomenological significance of altered states of consciousness
Lajos Horváth, Csaba Szummer, Attila Szabo
Phenomenology and the Cognitive Sciences, 2017, v tisku. DOI: 10.1007/s11097-016-9497-4


Clinical potential of psilocybin as a treatment for mental health conditions
Jeremy Daniel, Margaret Haberman
Mental Health Clinician, 2017, 7, 24-28. DOI: 10.9740/mhc.2017.01.024


Ayahuasca: An ancient sacrament for treatment of contemporary psychiatric illness?
Benjamin J. Malcolm and Kelly C. Lee (2017)
Mental Health Clinician, 2017, 7, 39-45. DOI: 10.9740/mhc.2017.01.039


A One-Dose Psychedelic Fix for Addiction?
Roni Jacobson
Scientific American Mind, 2017, 28, 10-11. DOI: 10.1038/scientificamericanmind0117-10


The Therapeutic Potential of Ayahuasca
Michael A. Coe, Dennis J. McKenna
v: Evidence-Based Herbal and Nutritional Treatments for Anxiety in Psychiatric Disorders II, 2017, str. 123-137. DOI: 10.1007/978-3-319-42307-4_7
pregledni članek


Tripping up addiction: the use of psychedelic drugs in the treatment of problematic drug and alcohol use
Celia Morgan, Amy McAndrew, Tobias Stevens, David Nutt, Will Lawn
Current Opinion in Behavioral Sciences, 2017, 13, 71–76. DOI: 10.1016/j.cobeha.2016.10.009





The History of Psychedelics in Medicine
Ben Sessa
v: M. von Heyden et al. (ur.), Handbuch Psychoaktive Substanzen, Springer Reference Psychologie, 2016. DOI 10.1007/978-3-642-55214-4_96-1


Psilocybin-assisted psychotherapy for dying cancer patients – aiding the final trip
David Spiegel
Journal of Psychopharmacology, 2016, 30, 1215-1217. DOI: 10.1177/0269881116675783


Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial
Roland R Griffiths, Matthew W Johnson, Michael A Carducci, Annie Umbricht, William A Richards, Brian D Richards, Mary P Cosimano, Margaret A Klinedinst
Journal of Psychopharmacology, 2016, 30, 1181–1197. DOI: 10.1177/0269881116675513


Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: a randomized controlled trial
Stephen Ross, Anthony Bossis, Jeffrey Guss, Gabrielle Agin-Liebes, Tara Malone, Barry Cohen, Sarah E. Mennenga, Alexander Belser, Krystallia Kalliontzi, James Babb, Zhe Su, Patricia Corby, Brian L. Schmidt
Journal of Psychopharmacology, 2016, 30, 1165–1180. DOI: 10.1177/0269881116675512


Psilocybin for depression and anxiety associated with life-threatening illnesses
John D McCorvy, Reid HJ Olsen, Bryan L Roth
Journal of Psychopharmacology, 2016, 30, 1209–1210. DOI: 10.1177/0269881116675771


Psycho-existential distress in cancer patients: A return to “entheogens”
Craig D Blinderman
Journal of Psychopharmacology, 2016, 30, 1205–1206. DOI: 10.1177/0269881116675761


The role of psychedelics in palliative care reconsidered: A case for psilocybin
Benjamin Kelmendi, Philip Corlett, Mohini Ranganathan, Cyril D’Souza, John H. Krystal
Journal of Psychopharmacology, 2016, 30, v tisku. DOI: 10.1177/0269881116675781


Serotonergic Hallucinogen-Induced Visual Perceptual Alterations
Michael Kometer, Franz X. Vollenweider
Current Topics in Behavioral Neurosciences, 2016, v tisku. DOI: 10.1007/7854_2016_461


Phenomenology, Structure, and Dynamic of Psychedelic States
Katrin H. Preller, Franz X. Vollenweider
Current Topics in Behavioral Neurosciences, 2016, v tisku. DOI: 10.1007/7854_2016_459


Can 3,4,-methylenedioxymethamphetamine therapy be used to treat alcohol use disorder?
Ben Sessa
Journal of Psychedelic Studies, 2016, v tisku. DOI: 10.1556/2054.01.2016.003


Treating drug dependence with the aid of ibogaine: A qualitative study
Eduardo Ekman Schenberg, Maria Angélica de Castro Comis, João Felipe Morel Alexandre, Bruno Daniel Rasmussen Chaves, Luís Fernando Tófoli, Dartiu Xavier da Silveira
Journal of Psychedelic Studies, 2016, v tisku. DOI: 10.1556/2054.01.2016.002


The antiaddictive effects of ibogaine: A systematic literature review of human studies
RG dos Santos, JC Bouso, JEC Hallak
Journal of Psychedelic Studies, 2016, v tisku. DOI: 10.1556/2054.01.2016.001


Effects of the Natural β-Carboline Alkaloid Harmine, a Main Constituent of Ayahuasca, in Memory and in the Hippocampus: A Systematic Literature Review of Preclinical Studies
Rafael G. dos Santos, Jaime E. C. Hallak
Journal of Psychoactive Drugs, 2016, v tisku. DOI: 10.1080/02791072.2016.1260189
pregledni članek


Harmine stimulates proliferation of human neural progenitors
Vanja Dakic, Renata de Moraes Maciel, Hannah Drummond, Juliana M. Nascimento, Pablo Trindade, Stevens K. Rehen
PeerJ, 2016, 4:e2727. DOI: 10.7717/peerj.2727


Back to the future: Research renewed on the clinical utility of psychedelic drugs
Jeffrey A Lieberman, Daniel Shalev
Journal of Psychopharmacology, 2016, 30, 1198-1200. DOI: 10.1177/0269881116675755


Arylcyclohexamines (Ketamine, Phencyclidine, and Analogues)
James H. Ho, Paul I. Dargan
Critical Care Toxicology, 2016, 91–46. DOI: 10.1007/978-3-319-20790-2_124-1


The Challenging Experience Questionnaire: Characterization of challenging experiences with psilocybin mushrooms
Frederick S Barrett, Matthew P. Bradstreet, Jeannie-Marie S Leoutsakos, Matthew W. Johnson, Roland R. Griffiths
J. Psychopharmacol., 2016, 30, 1279–1295. DOI: 10.1177/0269881116678781


Set and setting, psychedelics and the placebo response: An extra-pharmacological perspective on psychopharmacology
Ido Hartogsohn
J. Psychopharmacol., 2016, 30, 1259–1267. DOI: 10.1177/0269881116677852


A Review of Hallucinogen Persisting Perception Disorder (HPPD) and an Exploratory Study of Subjects Claiming Symptoms of HPPD
John H. Halpern, Arturo G. Lerner, Torsten Passie
Current Topics in Behavioral Neurosciences, 2016, 1-28. DOI: 10.1007/7854_2016_457


Classical hallucinogens and neuroimaging: a systematic review of human studies: Hallucinogens and neuroimaging
Rafael G. dos Santos, Flávia L. Osório, José Alexandre S. Crippaa, Jaime E.C. Hallak
Neuroscience & Biobehavioral Reviews, 2016, 71, 715–728. DOI: 10.1016/j.neubiorev.2016.10.026


Of Roots and Fruits: A Comparison of Psychedelic and Nonpsychedelic Mystical Experiences
David B. Yaden, Khoa D. Le Nguyen, Margaret L. Kern, Alexander B. Belser, Johannes C. Eichstaedt, Jonathan Iwry, Mary E. Smith, Nancy A. Wintering, Ralph W. Hood Jr., Andrew B. Newberg
Journal of Humanistic Psychology, 2016, v tisku. DOI: 10.1177/0022167816674625


Psychedelics in the treatment of unipolar mood disorders: A systematic review
J. Rucker, L. A. Jelen, S. Flynn, K. D. Frowde, A. Young
Journal of Psychopharmacology, 2016, v tisku.


Classic Psychedelics and Rational Suicide in the Elderly: Exploring the Potential Utility of a Reemerging Treatment Paradigm
Peter S. Hendricks, Charles S. Grob
DOI: 10.1007/978-3-319-32672-6_14
v:  Rational Suicide in the Elderly, 2016, ur. R. E. McCue, M. Balasubramaniam, str. 203-210 (Springer).


Lysergic Acid Diethylamide and mystical experiences
Michael Lyvers
DOI: 10.1016/B978-0-12-800212-4.00078-9
v: The neuropathology of drug addictions and substance misuse (Vol 2), 2016, ur. V. Preedy, str. 835-845 (Elsevier).


The Therapeutic Potentials of Ayahuasca: Possible Effects against Various Diseases of Civilization
Ede Frecska, Petra Bokor, Michael Winkelman
Front. Pharmacol., 2016, 7, e35. DOI: 10.3389/fphar.2016.00035
pregledni članek


Medicine, religion and ayahuasca in Catalonia. Considering ayahuasca networks from a medical anthropology perspective
Ismael Apud, Oriol Romaní
International Journal of Drug Policy, 2016, 39, 28-36. DOI: 10.1016/j.drugpo.2016.07.011


Creativity and Psychoactive Substance Use: A Systematic Review
Fruzsina Iszáj, Mark D. Griffiths, Zsolt Demetrovics
J. Ment. Health Addiction, 2016, v tisku. DOI: 10.1007/s11469-016-9709-8
pregledni članek


Transcultual Perspective on Consciousness: Traditional Use of Ayahuasca in Psychiatry in the 21st Century in the Western World
T. Re, J. Palma, J. E. Martins, M. Simões
Cosmos and History: The Journal of Natural and Social Philosophy, 2016, 12, 237-249.


The ethnobotany of psychoactive plant use: a phylogenetic perspective
Nashmiah Aid Alrashedy, Jeanmaire Molina
PeerJ, 2016, 4, e2546. DOI: 10.7717/peerj.2546


Alterations of consciousness and mystical-type experiences after acute LSD in humans
Matthias E. Liechti, Patrick C. Dolder, Yasmin Schmid
Psychopharmacology, 2016, v tisku. DOI: 10.1007/s00213-016-4453-0


The Transpersonal Potential of Psychedelics
C. W. Angelo
v: Shadows & Light (Volume 1: Principles & Practices): Theory, Research, and Practice in Transpersonal Psychology, 2016, ur. F. J. Kaklauskas, C. J. Clements, D. Hocoy, L. Hoffman (University Professors Press).


Development of a Psychotherapeutic Model for Psilocybin-Assisted Treatment of Alcoholism
Michael P. Bogenschutz, Alyssa A. Forcehimes
Journal of Humanistic Psychology, 2016, v tisku. DOI: 10.1177/0022167816673493


Ecstatic Landscapes: The Manifestation of Psychedelic Art
Stanley Krippner
Journal of Humanistic Psychology, 2016, v tisku. DOI: 10.1177/0022167816671579


Psychedelic Psychotherapy: Insights From 25 Years of Research
William A. Richards
Journal of Humanistic Psychology, 2016, v tisku. DOI: 10.1177/0022167816670996


Abraham Maslow’s Interest in Psychedelic Research: A Tribute
William A. Richards
Journal of Humanistic Psychology, 2016, v tisku. DOI: 10.1177/0022167816670997


Ayahuasca Treatment Center Safety for the Western Seeker
Raven Renèe Ray, Kerry S. Lassiter
Anthropology of Consciousness, 2016, 27, 121–150. DOI: 10.1111/anoc.12060


The Globalization of Ayahuasca Shamanism and the Erasure of Indigenous Shamanism
Evgenia Fotiou
Anthropology of Consciousness, 2016, 27, 151–179. DOI: 10.1111/anoc.12056


The Revitalization of Yajé Shamanism among the Siona: Strategies of Survival in Historical Context
Esther Jean Langdon
Anthropology of Consciousness, 2016, 27, 180–203. DOI: 10.1111/anoc.12058


Ayahuasca and Sumak Kawsay: Challenges to the Implementation of the Principle of “Buen Vivir,” Religious Freedom, and Cultural Heritage Protection
Carlos Teodoro J. H. Irigaray, Pierre Girard, Maíra Irigaray, Carolina Joana da Silva
Anthropology of Consciousness, 2016, 27, 204–225. DOI: 10.1111/anoc.12057


Psychological and neuropsychological assessment of regular hoasca users
Paulo Cesar Ribeiro Barbosa, Rick J. Strassman, Dartiu Xavier da Silveira, Kelsy Areco, Robert Hoya, Jessica Pommya, Robert Thoma, Michael Bogenschutz
Comprehensive Psychiatry, 2016, 71, 95–105. DOI: 10.1016/j.comppsych.2016.09.003


The Endogenous Hallucinogen and Trace Amine N,N-Dimethyltryptamine (DMT) Displays Potent Protective Effects against Hypoxia via Sigma-1 Receptor Activation in Human Primary iPSC-Derived Cortical Neurons and Microglia-Like Immune Cells
Attila Szabo, Attila Kovacs, Jordi Riba, Srdjan Djurovic, Eva Rajnavolgyi, Ede Frecska
Front. Neurosci., 2016, 10, 423. DOI: 10.3389/fnins.2016.00423


Sacred Bliss: A Spiritual History of Cannabis
Mark S. Ferrara, 2016 (Rowman & Littlefield). (google books preview)


Traditional marijuana, high-potency cannabis and synthetic cannabinoids: increasing risk for psychosis
R. M. Murray, H. Quigley, D. Quattrone, A. Englund, M. Di Forti
World Psychiatry, 15, 195–204. DOI: 10.1002/wps.20341
pregledni članek


Psychedelics Recruit Multiple Cellular Types and Produce Complex Transcriptional Responses Within the Brain
David A. Martin, Charles D. Nichols
EBioMedicine, 2016, 11, 262–277. DOI: 10.1016/j.ebiom.2016.08.049


The Discriminative Stimulus Properties of Hallucinogenic and Dissociative Anesthetic Drugs
Tomohisa Mori, Tsutomu Suzuki
Current Topics in Behavioral Neurosciences, 2016, 1-12. DOI: 10.1007/7854_2016_29


Brazil’s Ayahuasca Religions: Comparisons and Contrasts
A. Dawson
v: Handbook of Contemporary Religions in Brazil, 2016, ur. B. Schmidt, S. Engler, str. 233-252 (Brill). (google books preview)


The World Ayahuasca Diaspora: Reinventions and Controversies
ur. Beatriz Caiuby Labate, Clancy Cavnar, Alex K. Gearin, 2017 (Routledge). (google books preview)


Survey study of challenging experiences after ingesting psilocybin mushrooms: Acute and enduring positive and negative consequences
Theresa M. Carbonaro, Matthew P. Bradstreet, Frederick S. Barrett, Katherine A. MacLean, Robert Jesse, Matthew W. Johnson, Roland R. Griffiths
J. Psychopharmacol., 2016, 30, 1268-1278. DOI: 10.1177/0269881116662634

Medijske interpretacije: Researchers Urge Caution around Psilocybin Use;


Is There a Place for Psychedelics in Philosophy?: Fieldwork in Neuro- and Perennial Philosophy
Nicolas Langlitz
Common Knowledge, 2016, 22, 373-384. DOI: 10.1215/0961754X-3622224


Ketamine-Assisted Psychedelic Therapy
E. M. Krupitsky, A. I. Paley, T. N. Berkaliev, V. B. Ivanov, O. O. Dubrovina, D. A. Kozhnazarova, I. V. Dunaevsky, E. V. Rzhankova, A. Ya. Grinenko
International Journal of Transpersonal Studies, 2016, 15, 24-40.
pregledni članek


The effects of ecstasy on neurotransmitter systems: a review on the findings of molecular imaging studies
Yosta Vegting, Liesbeth Reneman, Jan Booij
Psychopharmacology, 2016, 233, 3473–3501. DOI: 10.1007/s00213-016-4396-5
pregledni članek


Return of the psychedelics: Psilocybin for treatment resistant depression
Suravi Patra
Asian Journal of Psychiatry, 2016, 24, 51–52. DOI: 10.1016/j.ajp.2016.08.010
pregledni članek


5-HT2A/5-HT2C Receptor Pharmacology and Intrinsic Clearance of N-Benzylphenethylamines Modified at the Primary Site of Metabolism
Sebastian Leth-Petersen, Ida N. Petersen, Anders A. Jensen, Christoffer Bundgaard, Mathias Bæk, Jan Kehler, and Jesper L. Kristensen
ACS Chem. Neurosci., 2016, 7, 1614–1619. DOI: 10.1021/acschemneuro.6b00265


The Entheogen Revolution
Thomas B. Roberts
The Journal of Transpersonal Psychology, 2016, 48, 26-33.


The antidepressant effect of ketamine: Mediated by AMPA receptors?
Dragos Inta, Rolf Sprengel, Stefan Borgwardt, Undine E. Lang, Peter Gass
European Neuropsychopharmacology, 2016, 26, 1692–1693. DOI: 10.1016/j.euroneuro.2016.08.002


The hallucinogen d-lysergic diethylamide (LSD) decreases dopamine firing activity through 5-HT1A, D2 and TAAR1 receptors
Danilo De Gregorio, Luca Posa, Rafael Ochoa-Sanchez, Ryan McLaughlin, Sabatino Maione, Stefano Comai, Gabriella Gobbi
Pharmacological Research, 2016, 113, 81–91. DOI: 10.1016/j.phrs.2016.08.022


Quantification of Anti-Addictive Alkaloids Ibogaine and Voacangine in in vivo- and in vitro-Grown Plants of Two Mexican Tabernaemontana Species
F. Krengel, J. H. Santoyo, T. de Jesús Olivera Flores, V. M. Chávez Ávila, F. J. Pérez Flores, R. Reyes Chilpa
Chem Biodiversity, 2016, 13, 1730–1737. DOI: 10.1002/cbdv.201600146


Ascending single-dose, double-blind, placebo-controlled safety study of noribogaine in opioid-dependent patients
P. Glue, G. Cape, D. Tunnicliff, M. Lockhart, F. Lam, N. Hung, C. T. Hung, S. Harland, J. Devane, R. S. Crockett, J. Howes, B. Darpo, M. Zhou, H. Weis, L. Friedhoff
Clinical pharmacology in Drug Development, 2016, 5, 460–468. DOI: 10.1002/cpdd.254


An intravenous self-administration procedure for assessing the reinforcing effects of hallucinogens in nonhuman primates
Amy K. Goodwin
Journal of Pharmacological and Toxicological Methods, 2016, 82, 31–36. DOI: 10.1016/j.vascn.2016.07.004


Ayahuasca enhances creative divergent thinking while decreasing conventional convergent thinking
K. P. C. Kuypers, J. Riba, M. de la Fuente Revenga, S. Barker, E. L. Theunissen, J. G. Ramaekers
Psychopharmacology, 2016, 233, 3395. DOI: 10.1007/s00213-016-4377-8


A Public-Health-Based Vision for the Management and Regulation of Psychedelics
Mark Haden, Brian Emerson, Kenneth W. Tupper
Journal of Psychoactive Drugs, 2016, 48, 243-252. DOI: 10.1080/02791072.2016.1202459


Treating Addiction: Perspectives from EEG and Imaging Studies on Psychedelics
L. F. Tófoli, D. B. de Araujo
International Review of Neurobiology, 2016, 129, 157–185. DOI: 10.1016/bs.irn.2016.06.005


Clinical applications of hallucinogens: A review
Albert Garcia-Romeu, Brennan Kersgaard, Peter H. Addy
Experimental and Clinical Psychopharmacology, 2016, 24, 229-268. DOI: 10.1037/pha0000084


Long-term follow-up of psilocybin-facilitated smoking cessation
Matthew W. Johnson, Albert Garcia-Romeu, Roland R. Griffiths
The American Journal of Drug and Alcohol Abuse, 2016, v tisku. DOI: 10.3109/00952990.2016.1170135

Medijske interpretacije: Can Magic Mushrooms Cure Addiction?; Live Every Day Like You’re on Mushrooms


What Neuroimaging of the Psychedelic State Tells Us about the Mind-Body Problem
Bernardo Kastrup
Journal of Cognition and Neuroethics, 2016, 4, 1–9.


From Psychiatry to Flower Power and Back Again: The Amazing Story of Lysergic Acid Diethylamide
Mucke Hermann A. M.
ASSAY and Drug Development Technologies, 2016, 14, 276-281. DOI: 10.1089/adt.2016.747


Ibogaine for treating drug dependence. What is a safe dose?
L. J. Schep, R. J. Slaughter, S. Galea, D. Newcombe
Drug and Alcohol Dependence, 2016, 166, 1–5. DOI: 10.1016/j.drugalcdep.2016.07.005


MDMA and PTSD Treatment
Ben Sessa
Neuroscience Letters, 2016, v tisku. DOI: 10.1016/j.neulet.2016.07.004


A Model for the Application of Target-Controlled Intravenous Infusion for a Prolonged Immersive DMT Psychedelic Experience
A. R. Gallimore, R. Strassman
Front. Pharmacol., 2016, 7, 211. DOI: 10.3389/fphar.2016.00211


Spirituality, drugs, and tourism: tourists’ and shamans’ experiences of ayahuasca in Iquitos, Peru
Girish Prayag, Paolo Mura, Colin Michael Hall, Julien Fontaine
Tourism Recreation Research, 2016, 41, 314-325. DOI: 10.1080/02508281.2016.1192237


Babyfat and Belladonna: Witches’ Ointment and the Contestation of Reality
Michael Ostling
Magic, Ritual, and Witchcraft, 2016, 11, 30-72. DOI: 10.1353/mrw.2016.0008


The current state of research on ayahuasca: A systematic review of human studies assessing psychiatric symptoms, neuropsychological functioning, and neuroimaging
Rafael G. dos Santos, Fermanda M. Balthazar, José C. Bouso, Jaime E. C. Hallak
J. Psychopharmacol., 2016, 30, 1230 – 1247. DOI: 10.1177/0269881116652578


Hallucinating the Slovenian Way: The Myth of Salamander Brandy, an Indigenous Slovenian Psychedelic Drug
Miha Kozorog
v: Edible Identities: Food as Cultural Heritage, 2016, ur. Ronda L. Brulotte, Michael A. Di Giovine, str. 125-139 (Routledge). (google books preview)


Potential involvement of serotonergic signaling in ketamine’s antidepressant actions: A critical review
Kristian Gaarn du Jardin, Heidi Kaastrup Müller, Betina Elfving, Elena Dale, Gregers Wegener, Connie Sanchez
Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2016, 71, 27–38. DOI: 10.1016/j.pnpbp.2016.05.007


Ketamine abuse potential and use disorder
Y. Liu, D. Lin, B. Wu, W. Zhou
Brain Research Bulletin, 2016, 126, 68–73. DOI: 10.1016/j.brainresbull.2016.05.016
pregledni članek


Effects of Ayahuasca and its Alkaloids on Drug Dependence: A Systematic Literature Review of Quantitative Studies in Animals and Humans
Amanda A. Nunes, Rafael G. dos Santos, Flávia L. Osório, Rafael F. Sanches, José Alexandre S. Crippa, Jaime E. C. Hallak
Journal of Psychoactive Drugs, 2016, 48, 195-205. DOI: 10.1080/02791072.2016.1188225


Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study
Robin L Carhart-Harris, Mark Bolstridge, James Rucker, Camilla M. J. Day, David Erritzoe,  Mendel Kaelen, Michael Bloomfield, James A. Rickard, Ben Forbes, Amanda Feilding, David Taylor, Steve Pilling, Valerie H. Curran, David J. Nutt
Lancet Psychiatry, 2016, 3, 619–627. DOI: 10.1016/S2215-0366(16)30065-7

Medijske interpretacije: Magic mushroom ingredient offers hope for treating depression


Prohibited or regulated? LSD psychotherapy and the United States Food and Drug Administration
Matthew Oram
History of Psychiatry, 2016, 27, 290-306. DOI: 10.1177/0957154X16648822


Remission of Severe Opioid Use Disorder with Ibogaine: A Case Report
L. Cloutier-Gill, E. Wood, T. Millar, C. Ferris, M. Eugenia Socias
Journal of Psychoactive Drugs, 2016, 48, 214-217. DOI: 10.1080/02791072.2016.1180467


Receptor interaction profiles of novel psychoactive tryptamines compared with classic hallucinogens
Anna Rickli, Olivier D. Moning, Marius C. Hoener, Matthias E. Liecht
European Neuropsychopharmacology, 2016, 26, 1327–1337. DOI: 10.1016/j.euroneuro.2016.05.001


Chemical Constituents of Plants from the Genus Psychotria
Hongmei Yang, Hongmei Zhang, Caiqiong Yang, Yegao Chen
Chemistry & Biodiversity, 2016, 13, 807–820. DOI: 10.1002/cbdv.201500259


Psychedelics Produce Complex And Heterogeneous Transcriptional Responses In Diverse Cortical Cell Types In The Brain Of Rats As Determined By New Flow Cytometric Methods Allowing For Sorting Of Distinct Cell And Neuronal Populations From Whole Brain
David Martin, Connie Porretta, Charles D. Nichols
FASEB J., 2016, 30, 930.3. DOI: 10.1096/fj.1530-6860


Molecular profile of dissociative drug ketamine in relation to its rapid antidepressant action
Joanna Ficek, Magdalena Zygmunt, Marcin Piechota, Dzesika Hoinkis, Jan Rodriguez Parkitna, Ryszard Przewlocki, Michal Korostynski
BMC Genomics, 2016, 17, 362. DOI: 10.1186/s12864-016-2713-3


Effects of low dose ibogaine on subjective mood state and psychological performance
Bridget Forsytha, Liana Machadoa, Tim Jowettb, Hannah Jakobic, Kira Garbec, Helen Winterd, Paul Glue
Journal of Ethnopharmacology, 2016, 189, 10–13. DOI: 10.1016/j.jep.2016.05.022


The paradoxical psychological effects of lysergic acid diethylamide (LSD)
R. L. Carhart-Harris, M. Kaelen, M. Bolstridge, T. M. Williams, L. T. Williams, R. Underwood, A. Feilding, D. J. Nutt
Psychological Medicine, 2016, 46, 1379-1390. DOI: 10.1017/S0033291715002901

Medijske interpretacije: Taking LSD leads to ‘improved psychological wellbeing’ – study; The psychedelic paradox; LSD: Psychedelic Thrill or Optimism Pill?


NMDAR inhibition-independent antidepressant actions of ketamine metabolites
Panos Zanos et al.
Nature, 2016, 533, 481–486. DOI: 10.1038/nature17998

Medijske interpretacije: Ketamine lifts depression via a byproduct of its metabolism


Practical application of the neuroregenerative properties of ketamine: real world treatment experience
T. A. Henderson
Neural. Regen. Res., 2016, 11, 195-200. DOI: 10.4103/1673-5374.177708


Exploring the therapeutic potential of Ayahuasca: acute intake increases mindfulness-related capacities
Joaquim Soler, Matilde Elices, Alba Franquesa, Steven Barker, Pablo Friedlander, Amanda Feilding, Juan C. Pascual, Jordi Riba
Psychopharmacology, 2016, 233, 823-829. DOI: 10.1007/s00213-015-4162-0


Has psychiatry tamed the “ketamine tiger?” Considerations on its use for depression and anxiety
Keith G. Rasmussen
Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2016, 64, 218–224. DOI: 10.1016/j.pnpbp.2015.01.002


LSD-induced entropic brain activity predicts subsequent personality change
A.V. Lebedev, M. Kaelen, M. Lövdén, J. Nilsson, A. Feilding, D.J. Nutt, R. L. Carhart-Harris
Human Brain Mapping, 2016, 37, 3203–3213. DOI: 10.1002/hbm.23234


LSD Alters Eyes-Closed Functional Connectivity within the Early Visual Cortex in a Retinotopic Fashion
Leor Roseman, Martin I. Sereno, Robert Leech, Mendel Kaelen, Csaba Orban, John McGonigle, Amanda Feilding, David J. Nutt, Robin L. Carhart-Harris
Human Brain Mapping, 2016, 37, 3031–3040. DOI: 10.1002/hbm.23224


Hallucinogen use and intimate partner violence: Prospective evidence consistent with protective effects among men with histories of problematic substance use
Zach Walsh, Peter S. Hendricks, Stephanie Smith, David S. Kosson, Michelle S. Thiessen, Philippe Lucas, Marc T. Swogger
J. Psychopharmacol., 2016, 30, 601-607. DOI: 10.1177/0269881116642538

Medijske interpretacije: Psychedelic drugs may reduce domestic violence; Magic mushrooms and LSD may prevent domestic violence by providing ‘spiritual experiences’


David Nichols
Pharmacological Reviews, 2016, 68, 264–355. DOI: 10.1124/pr.115.011478
(pregledni članek)


Decreased mental time travel to the past correlates with default-mode network disintegration under lysergic acid diethylamide
Jana Speth, Clemens Speth, Mendel Kaelen, Astrid M. Schloerscheidt, Amanda Feilding, David J. Nutt, Robin L. Carhart-Harris
J. Psychopharmacol, 2016, 30, 344-353. DOI: 10.1177/0269881116628430

Medijske interpretacije: Brain imaging study examines how LSD changes the way people think about time


LSD modulates music-induced imagery via changes in parahippocampal connectivity
Mendel Kaelen, Leor Roseman, Joshua Kahan, Andre Santos-Ribeiro, Csaba Orban, Romy Lorenz, Frederick S. Barrett, Mark Bolstridge, Tim Williams, Luke Williams, Matthew B. Wall, Amanda Feilding, Suresh Muthukumaraswamy, David J. Nutt, Robin Carhart-Harris
European Neuropsychopharmacology, 2016, 26, 1099–1109. DOI: 10.1016/j.euroneuro.2016.03.018

Medijske interpretacije: How to Pick Music for People on LSD, From a Scientist Whose Job That Is


Neural correlates of the LSD experience revealed by multimodal neuroimaging
Robin L. Carhart-Harris, Suresh Muthukumaraswamy, Leor Roseman, Mendel Kaelen, Wouter Droog, Kevin Murphy, Enzo Tagliazucchi, Eduardo E. Schenberg, Timothy Nest, Csaba Orban, Robert Leech, Luke T. Williams, Tim M. Williams, Mark Bolstridge, Ben Sessa, John McGonigle, Martin I. Sereno, David Nichols, Peter J. Hellyer, Peter Hobden, John Evans, Krish D. Singh, Richard G. Wise, H. Valerie Curran, Amanda Feilding, David J. Nutt
Proceedings of the National Academy of Sciences, 2016, 113, 4853–4858. DOI: 10.1073/pnas.1518377113

Medijske interpretacije: For the First Time, Scientists Have Imaged the Brain on LSD; Brain on LSD revealed: First scans show how the drug affects the brain


Effects of serotonin 2A/1A receptor stimulation on social exclusion processing
Katrin H. Preller, Thomas Pokorny, Andreas Hock, Rainer Kraehenmann, Philipp Stämpfli, Erich Seifritz, Milan Scheidegger, Franz X. Vollenweider
Proceedings of the National Academy of Sciences, 2016, 113, 5119-5124. DOI: 10.1073/pnas.1524187113

Medijske interpretacije: Feeling rejected? Mushrooms could help; Magic mushrooms can help reduce the pain of social rejection


MDMA-assisted therapy: A new treatment model for social anxiety in autistic adults
Alicia L. Danforth, Christopher M. Struble, Berra Yazar-Klosinski, Charles S. Grob
Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2016, 64, 237–249. DOI: 10.1016/j.pnpbp.2015.03.011


Modulatory effect of the 5-HT1A agonist buspirone and the mixed non-hallucinogenic 5-HT1A/2A agonist ergotamine on psilocybin-induced psychedelic experience
Thomas Pokorny, Katrin H. Preller, Rainer Kraehenmann, Franz X. Vollenweider
European Neuropsychopharmacology, 2016, 26, 756–766. DOI: 10.1016/j.euroneuro.2016.01.005


Classic hallucinogens in the treatment of addictions
Michael P. Bogenschutz, Matthew W. Johnson
Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2016, 64, 250–258. DOI: 10.1016/j.pnpbp.2015.03.002


Psychedelics and cognitive liberty: Reimagining drug policy through the prism of human rights
Charlotte Walsh
International Journal of Drug Policy, 2016, 29, 80-87. DOI: 10.1016/j.drugpo.2015.12.025


The epistemic innocence of psychedelic states
Chris Letheby
Consciousness and Cognition, 2016, 39, 28–37. DOI: 10.1016/j.concog.2015.11.012





LSD enhances the emotional response to music
M. Kaelen, F. S. Barrett, L. Roseman, R. Lorenz, N. Family, M. Bolstridge, H. V. Curran, A. Feilding, D. J. Nutt, R. L. Carhart-Harris
Psychopharmacology, 2015, 232, 3607-3614. DOI: 10.1007/s00213-015-4014-y


Psychedelic medicine: a re-emerging therapeutic paradigm
Kenneth W. Tupper, Evan Wood, Richard Yensen, Matthew W. Johnson
CMAJ, 2015, 187, 1054-1059. DOI: 10.1503/cmaj.141124
(pregledni članek)

Medijske interpretacije: Psychedelic medicine: a re-emerging therapeutic paradigm, PTSD and addiction; Psychedelic medicine is making a comeback


Psilocybin-assisted treatment for alcohol dependence: A proof-of-concept study
Michael P Bogenschutz, Alyssa A. Forcehimes, Jessica A. Pommy, Claire E. Wilcox, P. C. R. Barbosa, Rick J Strassman
J. Psychopharmacol., 2015, 29, 289-299. DOI: 10.1177/0269881114565144


Classic psychedelic use is associated with reduced psychological distress and suicidality in the United States adult population
Peter S. Hendricks, Christopher B. Thorne, C. Brendan Clark, David W. Coombs, Matthew W. Johnson
J. Psychopharmacol., 2015, 29, 280-288. DOI: 10.1177/0269881114565653


Psychedelics not linked to mental health problems or suicidal behavior: A population study
Pål-Ørjan Johansen, Teri Suzanne Krebs
J. Psychopharmacol, 2015, 29, 270-279. DOI: 10.1177/0269881114568039

Medijske interpretacije: No link found between psychedelics and psychosisPsychedelic drug use ‘does not increase risk for mental health problems’Seeing Opportunity in Psychedelic Drugs


Long-term use of psychedelic drugs is associated with differences in brain structure and personality in humans
José Carlos Bouso, Fernanda Palhano-Fontes, Antoni Rodríguez-Fornells, Sidarta Ribeiro, Rafael Sanches, José Alexandre S. Crippa, Jaime E.C. Hallak, Draulio B. de Araujo, Jordi Riba
European Neuropsychopharmacology, 2015, 25, 483–492. DOI: 10.1016/j.euroneuro.2015.01.008


Psychedelic drugs should be legally reclassified so that researchers can investigate their therapeutic potential
James J. H. Rucker
BMJ, 2015, 350:h2902. DOI: 10.1136/bmj.h2902

Medijske interpretacije: Psychedelic drugs should be legally reclassified as they may benefit patients, experts say


LSD-assisted psychotherapy for anxiety associated with a life-threatening disease: A qualitative study of acute and sustained subjective effects
Peter Gasser, Katharina Kirchner, Torsten Passie
J. Psychopharmacol., 2015, 29, 57-68. DOI: 10.1177/0269881114555249


Serotonin 5-HT2 receptor activation prevents allergic asthma in a mouse model
Felix Nau Jr., Justin Miller, Jordy Saravia, Terry Ahlert, Bangning Yu, Kyle I. Happel, Stephania A. Cormier, Charles D. Nichols
American Journal of Physiology – Lung Cellular and Molecular Physiology, 2015, 308, L191-L198.
DOI: 10.1152/ajplung.00138.2013


Recent advances in the neuropsychopharmacology of serotonergic hallucinogens
Adam L. Halberstadt
Behavioural Brain Research, 2015, 277, 99–120. DOI: 10.1016/j.bbr.2014.07.016


Can psychedelic compounds play a part in drug dependence therapy?
Ben Sessa, Matthew W. Johnson
British Journal of Psychiatry, 2015, 206, 1-3. DOI: 10.1192/bjp.bp.114.148031


Psychedelics and Immunomodulation: Novel Approaches and Therapeutic Opportunities
Attila Szabo
Front Immunol. 2015, 6, 358. DOI: 10.3389/fimmu.2015.00358


Serotonergic Psychedelics Temporarily Modify Information Transfer in Humans
Joan Francesc Alonso, Sergio Romero, Miquel Àngel Mañanas, Jordi Riba
International Journal of Neuropsychopharmacology, 2015, 18, 1-9. DOI: 10.1093/ijnp/pyv039


Restructuring consciousness -the psychedelic state in light of integrated information theory
A. R. Gallimore
Frontiers in Human Neuroscience, 2015, 9, 346. DOI: 10.3389/fnhum.2015.00346


The psychedelic state induced by ayahuasca modulates the activity and connectivity of the default mode network
F. Palhano-Fontes, K. C. Andrade, L. F. Tofoli, A. C. Santos, J. A. Crippa, J. E. Hallak, S. Ribeiro, D. B. de Araujo
PLoS One, 2015, 10, e0118143. DOI: 10.1371/journal.pone.0118143


Ascending-dose study of noribogaine in healthy volunteers: pharmacokinetics, pharmacodynamics, safety, and tolerability
P. Glue, M. Lockhart, F. Lam, N. Hung, C.-T. Hung, L. Friedhoff
J. Clin. pharmacol., 2015, 55, 189-194. DOI: 10.1002/jcph.404


Peak experiences and the afterglow phenomenon: when and how do therapeutic effects of hallucinogens depend on psychedelic experiences?
T. Majić, T. T. Schmidt, J. Gallinat
J. Psychopharmacol., 2015, 29, 241-253. DOI: 10.1177/0269881114568040


New World Tryptamine Hallucinogens and the Neuroscience of Ayahuasca
D. McKenna D,  J. Riba
Current Topics in Behavioral Neurosciences, 2015, 1-27. DOI: 10.1007/7854_2015_368


Salvinorin-A Induces Intense Dissociative Effects, Blocking External Sensory Perception and Modulating Interoception and Sense of Body Ownership in Humans
A. E. Maqueda, M. Valle M, P. H. Addy, R. M.  Antonijoan. M. Puntes, J. Coimbra, M. R. Ballester, M. Garrido, M. Gonzalez, J. Claramunt, S. Barker, M. W. Johnson, R. R. Griffiths, J. Riba
International Journal of Neuropsychopharmacology, 2015, 18, pyv065. DOI: 10.1093/ijnp/pyv065


Acute Effects of the Novel Psychoactive Drug 2C-B on Emotions
D. González, M. Torrens, M. Farré
Biomed Res Int., 2015, 643878. DOI: 10.1155/2015/643878


The Association of Salvia divinorum and Psychotic Disorders: A Review of the Literature and Case Series
Joseph El-Khoury, Nayiri Sahakian
Journal of Psychoactive Drugs, 2015, 47, 286-292. DOI: 10.1080/02791072.2015.1073815


Finding the self by losing the self: Neural correlates of ego-dissolution under psilocybin
Alexander V. Lebedev, Martin Lovden, Gidon Rosenthal, Amanda Feilding, David J. Nutt, Robin L. Carhart-Harris
Human Brain Mapping., 2015, 36, 3137-3153. DOI: 10.1002/hbm.22833


Mind navigators of chemicals’ experimenters? A web-based description of e-psychonauts
L. Orsolini, G. D. Papanti, G. Francesconi, F. Schifano
Cyberpsychol Behav Soc Netw., 2015, 18, 296-300. DOI: 10.1089/cyber.2014.0486






Psilocybin-Occasioned Mystical Experiences in the Treatment of Tobacco Addiction
Albert Garcia-Romeu, Roland R. Griffiths, Matthew W Johnson
Current Drug Abuse Reviews, 2014, 7, 157-164. DOI: 10.2174/1874473708666150107121331


Ayahuasca, Psychedelic Studies and Health Sciences: The Politics of Knowledge and Inquiry into an Amazonian Plant Brew
Kenneth W. Tupper, Beatriz C Labate
Current Drug Abuse Reviews, 2014, 7, 71-80. DOI: 10.2174/1874473708666150107155042


Psychedelics as Medicines for Substance Abuse Rehabilitation: Evaluating Treatments with LSD, Peyote, Ibogaine and Ayahuasca
Michael Winkelman
Current Drug Abuse Reviews, 2014, 7, 101-116. DOI: 10.2174/1874473708666150107120011


A Review of Lysergic Acid Diethylamide (LSD) in the Treatment of Addictions: Historical Perspectives and Future Prospects
Mitchell B Liester
Current Drug Abuse Reviews, 2014, 7, 146-156. DOI: 10.2174/1874473708666150107120522


A Qualitative Report on the Subjective Experience of Intravenous Psilocybin Administered in an fMRI Environment
S. Turton, D. J. Nutt, R. L. Carhart-Harris.
Current Drug Abuse Reviews, 2014, 7, 117-127. DOI: 10.2174/1874473708666150107120930


Salvinorin A and Related Compounds as Therapeutic Drugs for Psychostimulant-Related Disorders
R. G. dos Santos, J. A. S. Crippa, J. P. Machado-de-Sousa, J. E. C. Hallak.
Current Drug Abuse Reviews, 2014, 7, 128-132. DOI: 10.2174/1874473708666150107122741


What Can Neuroscience Tell Us About the Potential of Psychedelics in Healthcare? How the Neurophenomenology of Psychedelics Research Could Help us to Flourish Throughout Our Lives, as Well as to Enhance Our Dying
Robin Mackenzie
Current Drug Abuse Reviews, 2014, 7, 136-145. DOI: 10.2174/1874473708666150107114927


Pilot study of the 5-HT2AR agonist psilocybin in the treatment of tobacco addiction
Matthew W Johnson, Albert Garcia-Romeu, Mary P. Cosimano, Roland R. Griffiths
J. Psychopharmacol., 2014, 28, 983-992. DOI: 10.1177/0269881114548296


Psilocybin and Obsessive Compulsive Disorder
James Allen Wilcox
Journal of Psychoactive Drugs, 2014, 46, 393-395. DOI: 10.1080/02791072.2014.963754


Immunological Effects of Ayahuasca in Humans
Rafael Guimarães dos Santos
Journal of Psychoactive Drugs, 2014, 46, 383-388. DOI: 10.1080/02791072.2014.960113


Classical hallucinogens as antidepressants? A review of pharmacodynamics and putative clinical roles
David Baumeister, Georgina Barnes, Giovanni Giaroli, Derek Tracy
Therapeutic Advances in Psychopharmacology, 2014, 4, 156-169. DOI: 10.1177/2045125314527985
(pregledni članek)


Enhanced repertoire of brain dynamical states during the psychedelic experience
E. Tagliazucchi, R. Carhart-Harris, R. Leech, D. Nutt, D. R. Chialvo
Hum. Brain Mapp., 2014, 35, 5442–5456. DOI: 10.1002/hbm.22562


The effects of psilocybin and MDMA on between-network resting state functional connectivity in healthy volunteers
Leor Roseman, Robert Leech, Amanda Feilding, David J. Nutt, Robin L. Carhart-Harris
Front. Hum. Neurosci., 2014, 8, 1-11. DOI: 10.3389/fnhum.2014.00204


Psilocybin-Induced Decrease in Amygdala Reactivity Correlates with Enhanced Positive Mood in Healthy Volunteers
Rainer Kraehenmann, Katrin H. Preller, Milan Scheidegger, Thomas Pokorny, Oliver G. Bosch, Erich Seifritz, Franz X. Vollenweider
Biological Psychiatry, 2015, 78, 572–581. DOI: 10.1016/j.biopsych.2014.04.010


From Hofmann to the Haight Ashbury, and into the Future: The Past and Potential of Lysergic Acid Diethlyamide
David E. Smith, Glenn E. Raswyck, Leigh Dickerson Davidson
Journal of Psychoactive Drugs, 2014, 46, 3-10. DOI: 10.1080/02791072.2014.873684


Self-Experimentations with Psychedelics Among Mental Health Professionals: LSD in the Former Czechoslovakia
Petr Winkler, Ladislav Csémy
Journal of Psychoactive Drugs, 2014, 46, 11-19. DOI: 10.1080/02791072.2013.873158


The Heffter Research Institute: Past and Hopeful Future
David E. Nichols
Journal of Psychoactive Drugs, 2014, 46, 20-26. DOI: 10.1080/02791072.2014.873688


History and Future of the Multidisciplinary Association for Psychedelic Studies (MAPS)
Amy Emerson, Linnae Ponté, Lisa Jerome, Rick Doblin
Journal of Psychoactive Drugs, 2014, 46, 27-36. DOI: 10.1080/02791072.2014.877321


The Potential Dangers of Using MDMA for Psychotherapy
Andrew C. Parrott
Journal of Psychoactive Drugs, 2014, 46, 37-43. DOI: 10.1080/02791072.2014.873690


MDMA and the “Ecstasy Paradigm”
Jon C. Cole Ph.D.
Journal of Psychoactive Drugs, 2014, 46, 44-56. DOI: 10.1080/02791072.2014.878148


Why Psychiatry Needs Psychedelics and Psychedelics Need Psychiatry
Ben Sessa
Journal of Psychoactive Drugs, 2014, 46, 57-62. DOI: 10.1080/02791072.2014.877322


Therapeutic Effects of Ritual Ayahuasca Use in the Treatment of Substance Dependence—Qualitative Results
Anja Loizaga-Velder, Rolf Verres
Journal of Psychoactive Drugs, 2014, 46, 63-72. DOI: 10.1080/02791072.2013.873157


PTSD Symptom Reports of Patients Evaluated for the New Mexico Medical Cannabis Program
George R. Greer, Charles S. Grob, Adam L. Halberstadt
Journal of Psychoactive Drugs, 2014, 46, 73-77. DOI: 10.1080/02791072.2013.873843


Psilocybin – Summary of knowledge and new perspectives
Filip Tylš, Tomáš Páleníček, Jiří Horáček
European Neuropsychopharmacology, 2014, 24, 342–356. DOI: 10.1016/j.euroneuro.2013.12.006
(pregledni članek)






Ayahuasca-Assisted Therapy for Addiction: Results from a Preliminary Observational Study in Canada
Gerald Thomas, Philippe Lucas, N. Rielle Capler, Kenneth W. Tupper, Gina Martin
Current Drug Abuse Reviews, 2013, 6, 30-42. DOI: 10.2174/15733998113099990003


Ibogaine in the Treatment of Substance Dependence
Thomas Kingsley Brown
Current Drug Abuse Reviews, 2013, 6, 3-16. DOI: 10.2174/15672050113109990001


Can MDMA Play a Role in the Treatment of Substance Abuse?
Lisa Jerome, Shira Schuster, B Berra Yazar-Klosinski.
Current Drug Abuse Reviews, 2013, 6, 54-62. DOI: 10.2174/18744737112059990005


Studying the Effects of Classic Hallucinogens in the Treatment of Alcoholism: Rationale, Methodology, and Current Research with Psilocybin
Michael P Bogenschutz
Current Drug Abuse Reviews, 2013, 6, 17-29. DOI: 10.2174/15733998113099990002


Psychedelics and Mental Health: A Population Study
Teri S. Krebs, Pål-Ørjan Johansen
Plos One, 2016, 8, e63972. DOI: 10.1371/journal.pone.0063972

Medijske interpretacije: Data from U.S. survey casts doubt on U.S. classification of psychedelics as ‘dangerous’


Antidepressant effects of ketamine: mechanisms underlying fast-acting novel antidepressants
Caroline A. Browne, Irwin Lucki
Front. Pharmacol., 2013, 4, 161. DOI: 10.3389/fphar.2013.00161


Multiple conformations of 5-HT2A and 5-HT2C receptors in rat brain: an autoradiographic study with [125I](±)DOI
Juan F. López-Giménez, M. Teresa Vilaró, José M. Palacios, Guadalupe Mengod
Experimental Brain Research, 2013, 230, 395-406. DOI: 10.1007/s00221-013-3636-8


LC/MS/MS analysis of the endogenous dimethyltryptamine hallucinogens, their precursors, and major metabolites in rat pineal gland microdialysate
Steven A. Barker, Jimo Borjigin, Izabela Lomnicka, Rick Strassman
Biomedical Chromatography, 2013, 27, 1690–1700. DOI: 10.1002/bmc.2981


Ketamine: synaptogenesis, immunomodulation and glycogen synthase kinase-3 as underlying mechanisms of its antidepressant properties
P. A. Zunszain, M. A. Horowitz, A. Cattaneo, M. M. Lupi, C. M. Pariante
Molecular Psychiatry, 2013, 18, 1236–1241. DOI: 10.1038/mp.2013.87







Research on psychedelic substances
Simon D. Brandt, Torsten Passie
Drug Testing and Analysis, 2012, 4, 539–542. DOI: 10.1002/dta.1389


Therapeutic mechanisms of classic hallucinogens in the treatment of addictions: from indirect evidence to testable hypotheses
Michael P. Bogenschutz, Jessica M. Pommy
Drug Testing and Analysis, 2012, 4, 543–555. DOI: 10.1002/dta.1376


Head-twitch response in rodents induced by the hallucinogen 2,5-dimethoxy-4-iodoamphetamine: a comprehensive history, a re-evaluation of mechanisms, and its utility as a model
Clint E. Canal, Drake Morgan
Drug Testing and Analysis, 2012, 4, 556–576.DOI: 10.1002/dta.1333


Fluorine in psychedelic phenethylamines
Daniel Trachsel
Drug Testing and Analysis, 2012, 4, 577–590. DOI: 10.1002/dta.413


GC-MS and GC-IRD studies on brominated dimethoxyamphetamines: Regioisomers related to 4-Br-2,5-DMA (DOB)
Hadir M. Maher, Tamer Awad, Jack DeRuiter, C. Randall Clark
Drug Testing and Analysis, 2012, 4, 591–600. DOI: 10.1002/dta.409


Health status of ayahuasca users
Paulo Cesar Ribeiro Barbosa, Suely Mizumoto, Michael P. Bogenschutz and Rick J. Strassman
Drug Testing and Analysis, 2012, 4, 601–609. DOI: 10.1002/dta.1383


Metabolism and disposition of N,N-dimethyltryptamine and harmala alkaloids after oral administration of ayahuasca
Jordi Riba, Ethan H. McIlhenny, Marta Valle, José Carlos Bouso, Steven A. Barker
Drug Testing and Analysis, 2012, 4, 610–616. DOI: 10.1002/dta.1344


A critical review of reports of endogenous psychedelic N, N-dimethyltryptamines in humans: 1955–2010
Steven A. Barker, Ethan H. McIlhenny, Rick Strassman
Drug Testing and Analysis, 2012, 4, 617–635. DOI: 10.1002/dta.422


Analytical techniques for the determination of tryptamines and β-carbolines in plant matrices and in psychoactive beverages consumed during religious ceremonies and neo-shamanic urban practices
Alain Gaujac, Sandro Navickiene, Mark I. Collins, Simon D. Brandt, Jailson Bittencourt de Andrade
Drug Testing and Analysis, 2012, 4, 636–648. DOI: 10.1002/dta.1343